Ivabradina Tarbis Farma

Ivabradine, the active ingredient in Ivabradina Tarbis Farma, is a If channel inhibitor presented as an oral formulation for oral use. It reduces heart rate by selectively inhibiting the funny current in the sino‑atrial node and is indicated for chronic heart failure and stable angina pectoris in adult patients.

GNH USA supplies Ivabradina Tarbis Farma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for global distribution.

Ivabradine is used to manage conditions related to cardiac workload and heart rate. - Chronic heart failure with reduced ejection fraction: helps achieve target heart rate and may reduce hospitalization when added to guideline‑directed therapy. - Stable angina pectoris: relieves chest pain by lowering heart rate and myocardial oxygen demand. - Inadequate heart‑rate control despite beta‑blocker therapy: provides additional rate reduction without affecting contractility.

Ivabradine may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: heart rate below prescribed range. - Headache: mild to moderate intensity. - Dizziness: may occur on standing.

Serious or Rare Side Effects: - Atrial fibrillation: new onset arrhythmia. - Severe bradycardia requiring medical intervention. - Allergic reactions: rash, angioedema, or anaphylaxis.

When prescribing ivabradine, clinicians should consider several precautionary measures to ensure safe use. - Cardiac monitoring: assess heart rate and rhythm before and during therapy. - Concomitant beta‑blockers: avoid excessive bradycardia when combined. - Severe hepatic impairment: use with caution or avoid. - Pregnancy and lactation: safety not established; weigh benefits against risks. - Visual disturbances: discontinue if persistent luminous phenomena occur. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Ivabradine can interact with other medicines, influencing its plasma levels or cardiac effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ivabradine exposure, risk of bradycardia. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce efficacy, may require dose adjustment. - Concomitant ivabradine with other heart‑rate lowering agents (beta‑blockers, digoxin) at high doses: risk of severe bradycardia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may modestly raise ivabradine levels. - Antihypertensives: additive effect on blood pressure. - QT‑prolonging drugs: monitor cardiac rhythm.